Initiator Pharma (INIT) DNB Carnegie Healthcare Seminar 2026 summary

Company overview and funding

• Developing innovative monoamine modulating drugs for sexual dysfunction and pain, with a lead molecule, pudafensine, targeting dopamine.

• Listed on Nasdaq First North with a market cap of SEK 200 million and fully funded into 2027.

• Supported by over 3,500 shareholders, including cornerstone investors and a CRO partner.

• Experienced leadership team with strong clinical trial expertise.

Pipeline and clinical programs

• Pudafensine is being advanced in erectile dysfunction (ED), neuropathic pain (vulvodynia), and female sexual dysfunction.

• Phase II data in ED shows efficacy, especially for moderate to severe non-responders to current treatments.

• Vulvodynia program (Liberfem) is a first-in-class approach targeting central pain pathways, with a proof-of-concept trial ongoing.

• Preclinical data supports efficacy in female sexual dysfunction.

Market opportunity and differentiation

• Pudafensine offers a dual mechanism, acting centrally and peripherally, with no drug-drug interactions and strong safety profile.

• ED market is large and growing, with 30-40% of patients not responding to current PDE5 inhibitors.

• Vulvodynia affects over 30 million women in Europe and the US, with no approved therapies and a potential $1-4 billion annual peak sales.

• Pharma partners show increasing interest in both pain and sexual dysfunction indications.